Genfit S.A.
GNFT.PA
Get informed when a big investor buys or sells
+ FollowMarket Cap$445.68M
Close$
Share Statistics
| Market cap | $445.68 Million |
|---|---|
| Enterprise Value | $477.08 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -16.10% |
|---|---|
| Return on Assets | -3.90% |
| Return on Invested Capital | 3.51% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.56 |
| Enterprise Value to EBIT | 77.57 |
| Enterprise Value to Net Income | -57 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 2.65 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 28, 2026
EPS Estimate
$-0.16
Average shareholder expectationRevenue Estimate
$30.50 M
Average shareholder expectationNext Earnings Call
Expected Date
April 8, 2027
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
$37.20 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Genfit
130 employees
CEO: Pascal Prigent Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in...